Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin

World Journal of Hepatology

Volumn 7, Issue 8, 2015, Pages 1105-1111

  Ampuero, Javier ^a   Romero Gomez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Hepatocellular carcinoma; Mammalian target of rapamycin; Metabolic syndrome; Metformin; Statin

Indexed keywords

EID: 84929735936     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i8.1105     Document Type: Short Survey

References (61)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300]
2. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230 [PMID: 11088082]
3. El-Serag HB, Kanwal F. Obesity and hepatocellular carcinoma: hype and reality. Hepatology 2014; 60: 779-781 [PMID: 24753107 DOI: 10.1002/hep.27172]
4. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-1648 [PMID: 21544812 DOI: 10.1002/ijc.26165]
5. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18: 1642-1651 [PMID: 22529694 DOI: 10.3748/wjg.v18.i14.1642]
6. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, Kobayashi M, Morishita A, Kobara H, Mori H, Yoneyama H, Deguchi A, Himoto T, Kurokohchi K, Okano K, Suzuki Y, Murao K, Masaki T. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2014; 45: 322-332 [PMID: 24806290 DOI: 10.3892/ijo.2014.2419]
7. Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013; 84 Suppl 1: 93-97 [PMID: 23428866 DOI: 10.1159/000345897]
8. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005 [PMID: 20639898 DOI: 10.1038/onc.2010.236]
9. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014; 141: 160-171 [PMID: 24121058 DOI: 10.1016/j.pharmthera.2013.10.001]
10. Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012; 1: 83-93 [PMID: 24159576 DOI: 10.1159/000342405]
11. Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012; 1: 247-256 [PMID: 24159589 DOI: 10.1159/000343839]
12. Hou W, Liu J, Chen P, Wang H, Ye BC, Qiang F. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett 2014; 8: 1249-1254 [PMID: 25120700]
13. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010; 52: 921-929 [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034]
14. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929-1940 [PMID: 12673720]
15. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007; 83: 425-432 [PMID: 17318075]
16. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51 [PMID: 20175032 DOI: 10.1055/s-0030-1247131]
17. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99-109 [PMID: 6297757]
18. Wands JR, Kim M. WNT/ß-catenin signaling and hepatocellular carcinoma. Hepatology 2014; 60: 452-454 [PMID: 24644061 DOI: 10.1002/hep.27081]
19. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 2013; 59: 1107-1117 [PMID: 23835194 DOI: 10.1016/j.jhep.2013.07.001]
20. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009; 69: 2775-2782 [PMID: 19276364 DOI: 10.1158/0008-5472.CAN-08-3357]
21. Wang M, Xue L, Cao Q, Lin Y, Ding Y, Yang P, Che L. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 2009; 56: 533-541 [PMID: 19728763]
22. Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009; 8: 76 [PMID: 19778454 DOI: 10.1186/1476-4598-8-76]
23. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734 [PMID: 16915295]
24. Esposito K, Giugliano D. The association between metabolic syndrome and hepatocellular carcinoma: a missed meta-analysis. J Clin Gastroenterol 2014; 48: 742-743 [PMID: 24618507 DOI: 10.1097/MCG.0000000000000097]
25. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol 2008; 14: 5695-5700 [PMID: 18837086]
26. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702]
27. Qin L, Wang Y, Tao L, Wang Z. AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. J Biochem 2011; 150: 151-156 [PMID: 21616916 DOI: 10.1093/jb/mvr066]
28. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511 [PMID: 19469001]
29. Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15: 281-296, vii-x [PMID: 21689613 DOI: 10.1016/j.cld.2011.03.007]
30. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012; 24: 981-990 [PMID: 22286106 DOI: 10.1016/j.cellsig.2012.01.008]
31. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304 [PMID: 22266734 DOI: 10.2337/dc11-1313]
32. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes 2011; 3: 320-327 [PMID: 21631893 DOI: 10.1111/j.1753-0407.2011.00119.x]
33. Fang Z, Xu X, Zhou Z, Xu Z, Liu Z. Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells. Mol Med Rep 2014; 9: 2251-2256 [PMID: 24691570 DOI: 10.3892/mmr.2014.2097]
34. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 2012; 3: 865 [PMID: 22643892 DOI: 10.1038/ncomms1859]
35. Hyun B, Shin S, Lee A, Lee S, Song Y, Ha NJ, Cho KH, Kim K. Metformin Down-regulates TNF-α Secretion via Suppression of Scavenger Receptors in Macrophages. Immune Netw 2013; 13: 123-132 [PMID: 24009539 DOI: 10.4110/in.2013.13.4.123]
36. Takatani T, Minagawa M, Takatani R, Kinoshita K, Kohno Y. AMP-activated protein kinase attenuates Wnt/ß-catenin signaling in human osteoblastic Saos-2 cells. Mol Cell Endocrinol 2011; 339: 114-119 [PMID: 21501658 DOI: 10.1016/j.mce.2011.04.003]
37. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58: 745-749 [PMID: 19228809 DOI: 10.2337/db08-1028]
38. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1(OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431 [PMID: 17476361]
39. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012; 12: 109 [PMID: 22439694 DOI: 10.1186/1471-2407-12-109]
40. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461-6468 [PMID: 15374955]
41. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011; 71: 2286-2297 [PMID: 21262914 DOI: 10.1158/0008-5472.CAN-10-3367]
42. Ma Y, Chen Z, Zou Y, Ge J. Atorvastatin represses the angiotensin 2-induced oxidative stress and inflammatory response in dendritic cells via the PI3K/Akt/Nrf 2 pathway. Oxid Med Cell Longev 2014; 2014: 148798 [PMID: 25110549 DOI: 10.1155/2014/148798]
43. McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study. Curr Pharm Des 2014; 20: 1156-1160 [PMID: 24467235]
44. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946 [PMID: 20166205 DOI: 10.1002/cncr.24982]
45. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758 [PMID: 20331505 DOI: 10.1111/j.1478-3231.2010.02223.x]
46. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-2608 [PMID: 21752887 DOI: 10.1210/jc.2010-2415]
47. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52 [PMID: 22085817 DOI: 10.1038/ajg.2011.384]
48. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615 [PMID: 22773548 DOI: 10.1136/gutjnl-2011-301708]
49. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353 [PMID: 22523334 DOI: 10.1210/jc.2012-1267]
50. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891; quiz 892 [PMID: 23381014 DOI: 10.1038/ajg.2013.5]
51. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-1521 [PMID: 23509319 DOI: 10.1200/JCO.2012.44.6831]
52. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630 [PMID: 22271485 DOI: 10.1200/JCO.2011.36.0917]
53. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332 [PMID: 23063971 DOI: 10.1053/j.gastro.2012.10.005]
54. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914 [PMID: 23162861]
55. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849 [PMID: 22276132 DOI: 10.1371/journal.pone.0029849]
56. Singh S, Singh PP. Statins for prevention of hepatocellular cancer: one step closer? Hepatology 2014; 59: 724-726 [PMID: 23839991 DOI: 10.1002/hep.26614]
57. Carrat F. Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence? Clin Res Hepatol Gastroenterol 2014; 38: 9-11 [PMID: 24183917 DOI: 10.1016/j.clinre.2013.09.007]
58. Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero Mdel M, Maraver M, del Campo JA, Rojas Á, Camacho I, Figueruela B, Bautista JD, Romero-Gómez M. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 2012; 7: e49279 [PMID: 23166628 DOI: 10.1371/journal.pone.0049279]
59. Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther 2014; 39: 686-698 [PMID: 24612116]
60. Clément S, Peyrou M, Foti M, Negro F. Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms? J Clin Oncol 2013; 31: 4160-4161 [PMID: 24081939 DOI: 10.1200/JCO.2013.51.0354]
61. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 109: 325-334 [PMID: 24445574 DOI: 10.1038/ajg.2013.476]